Abstracts

Rationale: Lennox Gastaut Syndrome (LGS) produces significant economic costs for their chronic condition, with an impact of the patient's illness, his family and society. Objective: To determine the direct cost of SLG in a tertiary care hospital in Mexico Methods: We performed a cost analysis of the disease, using a generalized linear model from an institutional perspective of the health sector in Mexico. All costs are in Mexican pesos (MXP), updated to December de2011 Results: 58expedientes were reviewed of patients who met criteria of the International League Against Epilepsy for SLG and followed up for 5 years. The male gender predominance in 56% (n = 34), mean age 5 years 7 months to diagnosis. The average total cost of the first year of monitoring a patient is $ 38,974.60 SLG MxP, second year $ 31,534.27 MxP, third year $ 40,592.65 MxP, fourth year $ 13,522.84 MxP, fifth year $ 16,738.90 MxP. The greatest cost of illness is associated with hospitalizations during the first 3 years of follow up, while the last two years monitoring by the outer query is first followed by hospitalizations. Auxiliary diagnostic methods in third place and drugs in last place. Conclusions: The direct cost per year of SLG average follow-up from the institutional perspective is $ 28,272.65 MxP. The cost associated with hospitalizations for the highest morbidity in our series. It is necesary the timely management of patients with LGS to improve the quality of life and cost of illness by reducing comorbidities.